Journal
CANCER CELL
Volume 6, Issue 3, Pages 275-284Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2004.08.018
Keywords
-
Categories
Funding
- NCI NIH HHS [CA078512, CA90810, CA90270, CA88106, CA82976, CA103030] Funding Source: Medline
- NIDDK NIH HHS [DK67683] Funding Source: Medline
Ask authors/readers for more resources
We have recently identified glucose-regulated protein-78 (GRP78) as a relevant molecular target expressed in metastatic tumors by fingerprinting the circulating repertoire of antibodies from cancer patients. Here we design and evaluate a ligand-receptor system based on the tumor cell membrane expression of GRP78. We show that GRP78 binding peptide motifs target tumor cells specifically in vivo and in human cancer specimens ex vivo. Moreover, synthetic chimeric peptides composed of GRP78 binding motifs fused to a programmed cell death-inducing sequence can suppress tumor growth in xenograft and isogenic mouse models of prostate and breast cancer. Together, these preclinical data validate GRP78 on the tumor cell surface as a functional molecular target that may prove useful for translation into clinical applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available